BioAtla (BCAB) and Context Therapeutics (CNTX) Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362 Sep 23, 2024 07:31AM
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody Sep 23, 2024 07:30AM
Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors Dec 29, 2022 04:05PM